Julia D. Maltzman

1.6k total citations
29 papers, 1.2k citations indexed

About

Julia D. Maltzman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Julia D. Maltzman has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Julia D. Maltzman's work include Gastric Cancer Management and Outcomes (9 papers), Peptidase Inhibition and Analysis (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Julia D. Maltzman is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Peptidase Inhibition and Analysis (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (6 papers). Julia D. Maltzman collaborates with scholars based in United States, France and United Kingdom. Julia D. Maltzman's co-authors include Daniel J. O’Shannessy, Jean‐Jacques Kiladjian, Elliott F. Winton, Francisco Cervantes, Robert Smale, Elizabeth B. Somers, Yao‐Shi Fu, Ruben A. Mesa, Srđan Verstovšek and Raffit Hassan and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Julia D. Maltzman

28 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julia D. Maltzman United States 15 487 480 388 386 282 29 1.2k
Jan A. Burger United States 10 478 1.0× 956 2.0× 237 0.6× 278 0.7× 128 0.5× 26 1.6k
Becker Hewes United States 18 617 1.3× 457 1.0× 216 0.6× 1000 2.6× 393 1.4× 34 2.0k
Diane Healey United States 15 255 0.5× 262 0.5× 289 0.7× 931 2.4× 308 1.1× 33 1.4k
Paola Circosta Italy 17 649 1.3× 638 1.3× 259 0.7× 304 0.8× 88 0.3× 35 1.5k
Joanne I. Adamkewicz United States 13 373 0.8× 237 0.5× 733 1.9× 219 0.6× 155 0.5× 24 1.4k
Martin Kornacker Germany 20 380 0.8× 299 0.6× 138 0.4× 564 1.5× 160 0.6× 59 1.3k
Ralf Bieker Germany 20 920 1.9× 250 0.5× 727 1.9× 465 1.2× 142 0.5× 30 1.6k
Hidekazu Segawa Japan 15 317 0.7× 145 0.3× 233 0.6× 458 1.2× 175 0.6× 20 985
Joan García‐López Spain 14 259 0.5× 337 0.7× 510 1.3× 210 0.5× 47 0.2× 20 1.1k
Vittorio Abbonante Italy 17 308 0.6× 321 0.7× 428 1.1× 65 0.2× 72 0.3× 32 862

Countries citing papers authored by Julia D. Maltzman

Since Specialization
Citations

This map shows the geographic impact of Julia D. Maltzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia D. Maltzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia D. Maltzman more than expected).

Fields of papers citing papers by Julia D. Maltzman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia D. Maltzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia D. Maltzman. The network helps show where Julia D. Maltzman may publish in the future.

Co-authorship network of co-authors of Julia D. Maltzman

This figure shows the co-authorship network connecting the top 25 collaborators of Julia D. Maltzman. A scholar is included among the top collaborators of Julia D. Maltzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia D. Maltzman. Julia D. Maltzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Drakaki, Alexandra, Arash Rezazadeh Kalebasty, Jae‐Lyun Lee, et al.. (2020). Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.. Journal of Clinical Oncology. 38(6_suppl). TPS591–TPS591. 11 indexed citations
3.
Shah, Manish A., Alexander Starodub, Sunil Sharma, et al.. (2018). Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. Clinical Cancer Research. 24(16). 3829–3837. 78 indexed citations
4.
Mesa, Ruben A., Jean‐Jacques Kiladjian, John Catalano, et al.. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis. Journal of Clinical Oncology. 35(34). 3844–3850. 238 indexed citations
5.
Harrison, Claire, Alessandro M. Vannucchi, Uwe Platzbecker, et al.. (2017). Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. The Lancet Haematology. 5(2). e73–e81. 212 indexed citations
6.
Verstovšek, Srđan, Martin Grießhammer, Ruben A. Mesa, et al.. (2017). A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leukemia Research. 60. 11–17. 28 indexed citations
7.
Brachmann, Carrie Baker, Marianna Zavodovskaya, Jing Hu, et al.. (2017). Evaluating collagen neoepitopes as pharmacodynamic biomarkers of GS-5745, an MMP9 inhibitor, in advanced gastric cancer.. Journal of Clinical Oncology. 35(4_suppl). 58–58. 3 indexed citations
8.
Verstovšek, Srđan, Michael R. Savona, Ruben A. Mesa, et al.. (2017). A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis. British Journal of Haematology. 176(6). 939–949. 42 indexed citations
9.
Mesa, Ruben A., Jean‐Jacques Kiladjian, John Catalano, et al.. (2017). Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).. Journal of Clinical Oncology. 35(15_suppl). 7000–7000. 7 indexed citations
10.
Harrison, Claire, Alessandro M. Vannucchi, Uwe Platzbecker, et al.. (2017). Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. Journal of Clinical Oncology. 35(15_suppl). 7001–7001. 14 indexed citations
11.
12.
13.
Necela, Brian M., Jennifer A. Crozier, Cathy Andorfer, et al.. (2015). Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors. PLoS ONE. 10(3). e0122209–e0122209. 117 indexed citations
14.
Hassan, Raffit, Hedy L. Kindler, Thierry Jahan, et al.. (2014). Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. Clinical Cancer Research. 20(23). 5927–5936. 139 indexed citations
15.
Christoph, Daniel C., Cindy Tran, Julia D. Maltzman, et al.. (2014). Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer. 15(5). 320–330.e3. 14 indexed citations
16.
Thomas, Anish, Julia D. Maltzman, & Raffit Hassan. (2013). Farletuzumab in lung cancer. Lung Cancer. 80(1). 15–18. 20 indexed citations
17.
Crozier, Jennifer A., Brian M. Necela, E. Aubrey Thompson, et al.. (2013). Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target.. Journal of Clinical Oncology. 31(15_suppl). 1037–1037. 5 indexed citations
18.
Christoph, Daniel C., Bernadette Reyna Asuncion, Cindy Tran, et al.. (2012). Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed. Journal of Thoracic Oncology. 8(1). 19–30. 72 indexed citations
19.
20.
Johnston, Stephen, et al.. (2009). Baseline serum extracellular domain HER2 expression in hormone receptor-positive metastatic breast cancer: correlation with known tissue HER2 status.. Cancer Research. 69(2_Supplement). 3147–3147. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan A. Burger Breakdown of academic impact, for papers by Becker Hewes Breakdown of academic impact, for papers by Diane Healey Breakdown of academic impact, for papers by Paola Circosta Breakdown of academic impact, for papers by Joanne I. Adamkewicz Breakdown of academic impact, for papers by Martin Kornacker Breakdown of academic impact, for papers by Ralf Bieker Breakdown of academic impact, for papers by Hidekazu Segawa Breakdown of academic impact, for papers by Joan García‐López Breakdown of academic impact, for papers by Vittorio Abbonante
Rankless by CCL
2026